vs
Avantor, Inc.（AVTR）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是罗布乐思的1.2倍（$1.7B vs $1.4B），Avantor, Inc.净利率更高（3.1% vs -22.3%，领先25.5%），罗布乐思同比增速更快（43.2% vs -1.4%），罗布乐思自由现金流更多（$308.6M vs $117.2M），过去两年罗布乐思的营收复合增速更高（32.9% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
AVTR vs RBLX — 直观对比
营收规模更大
AVTR
是对方的1.2倍
$1.4B
营收增速更快
RBLX
高出44.6%
-1.4%
净利率更高
AVTR
高出25.5%
-22.3%
自由现金流更多
RBLX
多$191.4M
$117.2M
两年增速更快
RBLX
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.4B |
| 净利润 | $52.4M | $-316.0M |
| 毛利率 | 31.5% | 77.7% |
| 营业利润率 | 7.6% | -25.3% |
| 净利率 | 3.1% | -22.3% |
| 营收同比 | -1.4% | 43.2% |
| 净利润同比 | -89.5% | -43.9% |
| 每股收益（稀释后） | $0.08 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRRBLX
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.6B | $1.4B | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.6B | $1.0B | ||
| Q4 24 | $1.7B | $988.2M | ||
| Q3 24 | $1.7B | $919.0M | ||
| Q2 24 | $1.7B | $893.5M | ||
| Q1 24 | $1.7B | $801.3M |
净利润AVTRRBLX
| Q4 25 | $52.4M | $-316.0M | ||
| Q3 25 | $-711.8M | $-255.6M | ||
| Q2 25 | $64.7M | $-278.4M | ||
| Q1 25 | $64.5M | $-215.1M | ||
| Q4 24 | $500.4M | $-219.6M | ||
| Q3 24 | $57.8M | $-239.3M | ||
| Q2 24 | $92.9M | $-205.9M | ||
| Q1 24 | $60.4M | $-270.6M |
毛利率AVTRRBLX
| Q4 25 | 31.5% | 77.7% | ||
| Q3 25 | 32.4% | 78.2% | ||
| Q2 25 | 32.9% | 78.2% | ||
| Q1 25 | 33.8% | 78.3% | ||
| Q4 24 | 33.4% | 77.9% | ||
| Q3 24 | 32.9% | 77.7% | ||
| Q2 24 | 34.1% | 77.8% | ||
| Q1 24 | 34.0% | 77.7% |
营业利润率AVTRRBLX
| Q4 25 | 7.6% | -25.3% | ||
| Q3 25 | -40.0% | -21.8% | ||
| Q2 25 | 7.7% | -29.8% | ||
| Q1 25 | 9.3% | -24.6% | ||
| Q4 24 | 37.8% | -24.7% | ||
| Q3 24 | 7.3% | -30.4% | ||
| Q2 24 | 10.3% | -26.6% | ||
| Q1 24 | 8.7% | -37.7% |
净利率AVTRRBLX
| Q4 25 | 3.1% | -22.3% | ||
| Q3 25 | -43.8% | -18.8% | ||
| Q2 25 | 3.8% | -25.8% | ||
| Q1 25 | 4.1% | -20.8% | ||
| Q4 24 | 29.7% | -22.2% | ||
| Q3 24 | 3.4% | -26.0% | ||
| Q2 24 | 5.5% | -23.0% | ||
| Q1 24 | 3.6% | -33.8% |
每股收益（稀释后）AVTRRBLX
| Q4 25 | $0.08 | $-0.44 | ||
| Q3 25 | $-1.04 | $-0.37 | ||
| Q2 25 | $0.09 | $-0.41 | ||
| Q1 25 | $0.09 | $-0.32 | ||
| Q4 24 | $0.73 | $-0.32 | ||
| Q3 24 | $0.08 | $-0.37 | ||
| Q2 24 | $0.14 | $-0.32 | ||
| Q1 24 | $0.09 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $3.1B |
| 总债务越低越好 | $3.9B | $1.2B |
| 股东权益账面价值 | $5.6B | $394.5M |
| 总资产 | $11.8B | $9.6B |
| 负债/权益比越低杠杆越低 | 0.71× | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资AVTRRBLX
| Q4 25 | $365.4M | $3.1B | ||
| Q3 25 | $251.9M | $2.9B | ||
| Q2 25 | $449.4M | $2.6B | ||
| Q1 25 | $315.7M | $2.7B | ||
| Q4 24 | $261.9M | $2.4B | ||
| Q3 24 | $285.3M | $2.3B | ||
| Q2 24 | $272.6M | $2.4B | ||
| Q1 24 | $234.9M | $2.4B |
总债务AVTRRBLX
| Q4 25 | $3.9B | $1.2B | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | $1.2B | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRRBLX
| Q4 25 | $5.6B | $394.5M | ||
| Q3 25 | $5.6B | $407.6M | ||
| Q2 25 | $6.3B | $353.2M | ||
| Q1 25 | $6.1B | $310.7M | ||
| Q4 24 | $6.0B | $221.4M | ||
| Q3 24 | $5.6B | $189.9M | ||
| Q2 24 | $5.4B | $121.5M | ||
| Q1 24 | $5.3B | $71.6M |
总资产AVTRRBLX
| Q4 25 | $11.8B | $9.6B | ||
| Q3 25 | $11.7B | $8.6B | ||
| Q2 25 | $12.8B | $7.8B | ||
| Q1 25 | $12.3B | $7.5B | ||
| Q4 24 | $12.1B | $7.2B | ||
| Q3 24 | $12.8B | $6.7B | ||
| Q2 24 | $12.7B | $6.5B | ||
| Q1 24 | $12.8B | $6.3B |
负债/权益比AVTRRBLX
| Q4 25 | 0.71× | 2.98× | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | 5.48× | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $308.6M |
| 自由现金流率自由现金流/营收 | 7.0% | 21.8% |
| 资本支出强度资本支出/营收 | 2.1% | 21.1% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $1.4B |
8季度趋势，按日历期对齐
经营现金流AVTRRBLX
| Q4 25 | $152.7M | $607.0M | ||
| Q3 25 | $207.4M | $546.2M | ||
| Q2 25 | $154.4M | $199.3M | ||
| Q1 25 | $109.3M | $443.9M | ||
| Q4 24 | $173.3M | $184.5M | ||
| Q3 24 | $244.8M | $247.4M | ||
| Q2 24 | $281.1M | $151.4M | ||
| Q1 24 | $141.6M | $238.9M |
自由现金流AVTRRBLX
| Q4 25 | $117.2M | $308.6M | ||
| Q3 25 | $171.7M | $443.6M | ||
| Q2 25 | $124.8M | $176.7M | ||
| Q1 25 | $81.3M | $426.5M | ||
| Q4 24 | $145.8M | $120.6M | ||
| Q3 24 | $204.0M | $218.0M | ||
| Q2 24 | $235.3M | $111.7M | ||
| Q1 24 | $106.9M | $192.3M |
自由现金流率AVTRRBLX
| Q4 25 | 7.0% | 21.8% | ||
| Q3 25 | 10.6% | 32.6% | ||
| Q2 25 | 7.4% | 16.3% | ||
| Q1 25 | 5.1% | 41.2% | ||
| Q4 24 | 8.6% | 12.2% | ||
| Q3 24 | 11.9% | 23.7% | ||
| Q2 24 | 13.8% | 12.5% | ||
| Q1 24 | 6.4% | 24.0% |
资本支出强度AVTRRBLX
| Q4 25 | 2.1% | 21.1% | ||
| Q3 25 | 2.2% | 7.5% | ||
| Q2 25 | 1.8% | 2.1% | ||
| Q1 25 | 1.8% | 1.7% | ||
| Q4 24 | 1.6% | 6.5% | ||
| Q3 24 | 2.4% | 3.2% | ||
| Q2 24 | 2.7% | 4.4% | ||
| Q1 24 | 2.1% | 5.8% |
现金转化率AVTRRBLX
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
RBLX
暂无分部数据
